OverT is redefining what's possible for treating solid tumors with programmed, off-the-shelf cell therapies.
Investors 1
Mentions in press and media 4
| Date | Title | Description |
| 09.10.2024 | Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors | CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, a New York-based b... |
| 06.05.2024 | OverT Bio Raises $16M in Seed Funding | OverT Bio, a NYC-based data-driven company working to enable the curative potential of cell therapies in solid tumors, raised $16M in Seed funding.
The round was led by ARTIS Ventures and Wing VC, with participation from Fusion Fund, OMX Ve... |
| 06.05.2024 | OverT Bio Secures $16M to Optimize Cell Therapy for Solid Tumors | What You Should Know:
– OverT Bio, a data-driven biotech company focused on unlocking the curative potential of cell therapies for solid tumors raises $16M in seed funding round. Co-led by ARTIS Ventures and Wing VC, the round saw participa... |
| - | OverT Bio | “OverT Bio” |
Reviews 0
